Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | NPY4R | P50391 | 7/20 | 0.42 |
| ▸ | NPY1R | P25929 | 4/20 | 0.42 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31481586 | 0.90 | OPRK1 (0.47) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL11101528 | 0.88 | OPRK1 (0.48) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL11101521 | 0.88 | OPRK1 (0.48) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL11644393 | 0.88 | OPRK1 (0.43) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL9616907 | 0.88 | OPRK1 (0.43) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL9616909 | 0.88 | OPRK1 (0.43) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL29510980 | 0.86 | NPY4R (0.55) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30118984 | 0.84 | OPRK1 (0.47) | OPRK1OPRM1 | |
| SCHEMBL29607765 | 0.83 | OPRK1 (0.55) | OPRK1OPRM1 | |
| SCHEMBL31467772 | 0.83 | EPHA2 (0.41) | OPRK1OPRM1NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249493-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2022115443-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-02 | — | — | WO | disclosed |